Evidence map›Paper›PMID 33792841›Full record

GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

SEOM clinical guideline for management of adult medulloblastoma (2020).

R Luque, M Benavides, S Del Barco, L Egaña, J García-Gómez, M Martínez-García, P Pérez-Segura, E Pineda, J M Sepúlveda, M Vieito

Open access · hybridAbstract readPractice Guideline
In one paragraph

Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

R LuqueDepartment of Medical Oncology, Hospital Universitario Virgen de Las Nieves, Granada, Spain. rluquecaro@gmail.com.
M BenavidesDepartment of Medical Oncology, Hospital Regional Universitario Carlos Haya, Malaga, Spain.
S Del BarcoDepartment of Medical Oncology, Hospital Universitari Dr. Josep Trueta. ICO Girona, Girona, Spain.
L EgañaDepartment of Medical Oncology, Hospital Donostia-Donostia Ospitalea, San Sebastián, Spain.
J García-GómezDepartment of Medical Oncology, Complexo Hospitalario de Ourense (CHUO), Orense, Spain.
M Martínez-GarcíaDepartment of Medical Oncology, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain.
P Pérez-SeguraDepartment of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
E PinedaDepartment of Medical Oncology, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2128-747X
J M SepúlvedaDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
M VieitoDepartment of Medical Oncology, Hospital Universitario Vall D'Hebron, Barcelona, Spain.
Complejo Hospitalario de Ourense · ESDonostiako Unibertsitate Ospitalea · ESHospital Clínic de Barcelona · ESHospital Clínico San Carlos · ESHospital Regional Universitario de Málaga · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitario 12 De Octubre · ESHospital Universitario Virgen de las Nieves · ESParc de Salut · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in molecular profiling, have reclassified medulloblastoma, an undifferentiated tumor of the posterior fossa, in at least four diseases, each one with differences in prognosis, epidemiology and sensibility to different treatments. The recommended management of a lesion with radiological characteristics suggestive of MB includes maximum safe resection followed by a post-surgical MR < 48 h, LCR cytology and MR of the neuroaxis. Prognostic factors, such as presence of a residual tumor volume > 1.5 cm

Indexed as

AdultAntineoplastic AgentsCerebellar NeoplasmsCisplatinCombined Modality TherapyEvidence-Based MedicineHumansMedical OncologyMedulloblastomaMolecular Targeted TherapyNeoplasm Recurrence, LocalPalliative CarePostoperative ComplicationsPrognosisRadiotherapyRetreatmentAntineoplastic AgentsCisplatinVincristineAdultsMedulloblastomaTreatment

Identifiers

PMID33792841
PMCPMC8057961
OpenAlexW3140417581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.